The importance of uncommon/rare oncogenic drivers in non‐small cell lung cancer (NSCLC) was underscored during the 20th China Lung Cancer Summit. These drivers, while present in a significant proportion of NSCLC patients, remain a challenge for diagnosis and therapeutic targeting. In the never‐smokers/low smokers category with mutations such as EGFR and HER2, the efficacy of immune checkpoint inhibitors (ICIs) remains suboptimal, attributed to lower PD‐L1 expression and tumor mutation burden (TMB). However, heavy smokers, often with mutations like KRAS, may derive benefits from ICIs, as supported by trials like CheckMate‐057. With the complex landscape of these drivers and their clinical implications, the summit culminated in six pivotal consensus points, aiming to guide future research and clinical decisions. Despite the advancements, the detection, interpretation, and therapeutic strategies involving these drivers necessitate further exploration and standardization.
Publications
- Article type
- Year
- Co-author
Article type
Year
Open Access
Clinical Guideline
Issue
Medicine Advances 2023, 1 (4): 293-305
Published: 12 December 2023
Downloads:4
Open Access
Commentary
Issue
Medicine Advances 2023, 1 (1): 89-91
Published: 24 March 2023
Downloads:19
Open Access
Perspective
Issue
Cancer Biology & Medicine 2022, 19 (5): 569-572
Published: 24 June 2022
Downloads:0
total 3